The Armageddon scenario, page-34

First 34 Last

Share
Profile

Follow
sarge17

3,478 Posts.

828

13/12/23

11:48

Post #: 71423079
Share

Originally posted by sarge17: ↑

In my opinion, most rational people would have to concede/agree that Starpharma’s three SPL7013 commercialised products (Fleurstat, condoms and Viraleze) have been commercial flops so far.

VivaGel BV/Fleurstat was for many years touted as being a company maker in it’s own right. This product was expected to produce rivers of gold which would then allow Starpharma to aggressively and perpetually fund development of in-house DEP drugs. Sadly this has not occurred.

So we turn to in-house DEP drug development. It is becoming apparent IMO that the lead drug DEP-Docetaxel will not be developed past this never-ending Phase 2 trial which CEO Fairley initially indicated would be complete in late 2018.) The other two internal drugs, who knows, but the completion of Phase 2 keeps getting pushed to the further and further to the right. So it’s possible IMO that these may not be progressed as expected or licenced out either.

Therefore, so much now relies on the AstraZeneca partnership more than ever before IMO. Most of Starpharma’s enterprise valuation is based on this promising partnership and collaboration. However and it’s a big however, the reality is that these AZD0466 trials are still in the Phase 1 part of the much touted ‘seamless’ Phase1/2 trials. Facts and stats back up that the majority of trials fall over before completing Phase 1 because of unexpected issues.

I truly hope that AstraZeneca and Starpharma progress one or two AZD0466 trials into Phase 2. This would be a massive milestone and catalyst. But until then, Starpharma IMO are heavily dependent on AstraZeneca to justify the current market capitalisation.

God help the share price is AstraZeneca suspend or terminate even one AZD0466 trial. Food for thought anyway.

GLTAH

Expand

The big domino to fall was the AZD0466 trial with AstraZeneca. Will the DEP-Doceraxel results herald a new dawn? I personally doubt it IMHO but wouldn’t it be great if they were, despite being 5 years late!

It would therefore appear a lot is riding on the Viraleze trial results due *cough any day now. I really hope they are stellar.

SPL Price at posting: 13.0¢ Sentiment: Sell Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

What's causing the cost-of-living crisis, and how to navigate it

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war